Medical Devices · NYSE: EW
Edwards Lifesciences earnings: results, call transcripts & KPI history
2 quarters · fiscal year ends December · next results expected around 9 Feb 2027
Latest: Q3 2026
Edwards raised its 2026 outlook after TAVR share gains and a new CMS coverage decision, while TMTT growth from PASCAL and EVOQUE added a second structural heart engine.
Edwards' TAVR business grew on a heightened clinical focus on treating aortic stenosis earlier, with modest share gains and stable pricing. CMS finalized an updated TAVR coverage policy, and Japan granted dedicated reimbursement for SAPIEN 3 Ultra RESILIA. In mitral and tricuspid, mitral and tricuspid procedure volumes grew in double digits, and the FDA approved PASCAL Ace with Capture Clarity and PASCAL Precision for tricuspid.
Quarters
KPI history
Fourth quarter worked out from the annual figure.
Data
| Q4 2024 | $1.4B |
| Q1 2025 | $1.4B |
| Q2 2025 | $1.5B |
| Q3 2025 | $1.6B |
| Q4 2025 | $1.6B * |
| Q1 2026 | $1.6B |
| Q2 2026 | $1.7B |
| Q3 2026 | $1.7B |
Data
| Q4 2024 | $0.65 |
| Q1 2025 | $0.61 |
| Q2 2025 | $0.56 |
| Q3 2025 | $0.50 |
| Q1 2026 | $0.66 |
| Q2 2026 | $0.42 |
| Q3 2026 | $0.53 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 2024 | 22.6% |
| Q1 2025 | 27.9% |
| Q2 2025 | 26.8% |
| Q3 2025 | 19.8% |
| Q4 2025 | 9.6% |
| Q1 2026 | 29.0% |
| Q2 2026 | 29.5% |
| Q3 2026 | 17.4% |
Data
| Q4 2024 | -$177.3M |
| Q1 2025 | $224.4M |
| Q2 2025 | $240.9M |
| Q3 2025 | $516.2M |
| Q4 2025 | $353.5M |
| Q1 2026 | -$21.1M |
| Q2 2026 | $585.0M |
| Q3 2026 | $506.7M |
Operating cash flow minus capital expenditure, from cash flow statements.
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4B | $1.4B | $1.5B | $1.6B | $1.6Bd | $1.6B | $1.7B | $1.7B |
| Gross margin | 78.9% | 78.7% | 77.5% | 77.8% | 78.1% | 78.0% | 77.5% | 78.5% |
| Operating income | $312.6Md | $394.8M | $411.2M | $307.1M | $151.1Md | $477.6M | $513.2M | $299.1M |
| Operating margin | 22.6% | 27.9% | 26.8% | 19.8% | 9.6% | 29.0% | 29.5% | 17.4% |
| Net income | $385.6M | $358.0M | $333.2M | $291.1M | $91.2Md | $380.7M | $241.9M | $307.5M |
| Diluted EPS | $0.65 | $0.61 | $0.56 | $0.50 | — | $0.66 | $0.42 | $0.53 |
| Operating cash flow | -$127.5Md | $280.4M | $290.2Md | $573.7Md | $450.9Md | $43.8M | $651.9Md | $570.3Md |
| Capital expenditure | $49.8Md | $56.0M | $49.3Md | $57.5Md | $97.4Md | $64.9M | $66.9Md | $63.6Md |
| Free cash flow | -$177.3M | $224.4M | $240.9M | $516.2M | $353.5M | -$21.1M | $585.0M | $506.7M |
| R&D expense | $271.1Md | $254.6M | $276.2M | $280.7M | $267.7Md | $263.3M | $278.9M | $281.4M |
From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.
10-K and 10-Q filings
- 4 Nov 202610-Q for the period ended 30 Sep 2026SEC ↗
- 4 Aug 202610-Q for the period ended 30 Jun 2026SEC ↗
- 6 May 202610-Q for the period ended 31 Mar 2026SEC ↗
- 25 Feb 202610-K for the period ended 31 Dec 2025SEC ↗
- 5 Nov 202510-Q for the period ended 30 Sep 2025SEC ↗
- 6 Aug 202510-Q for the period ended 30 Jun 2025SEC ↗
- 6 May 202510-Q for the period ended 31 Mar 2025SEC ↗
- 28 Feb 202510-K for the period ended 31 Dec 2024SEC ↗